FDA Drug Reviews Pass Muster As User Fee Deadline Looms
Supporters of the U.S. Food and Drug Administration got some ammo to use against potential opponents of the user fee reauthorization package Monday, when the U.S. Government Accountability Office reported that...To view the full article, register now.
Already a subscriber? Click here to view full article